Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Shore N, Powles TB, Bedke J, Galsky MD, Kopyltsov E, Necchi A, Palou Redorta J, Vermette JJ, Randall AE, Pierce KJ, Cesari R, Steinberg GD June 4, 2022 ASCO 2022 Urothelial Cancer

A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B 

View Presentation View Abstract Plain Language Summary
Poster
Valderrama BP, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg CN, Wang J, Costa N, Laliberte RJ, di Pietro A, Park SH, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to First-Line Chemotherapy

View Presentation View Abstract Plain Language Summary
Poster
Liu FX, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Thakkar S, Devgan G, Katzenstein H June 4, 2022 ASCO 2022 Urothelial Cancer

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

View Presentation
Poster
Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, di Pietro A, Huang B, Gupta S, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Oral Presentation
Powles T, Sridhar SS, Bellmunt J, Sternberg CN, Grivas P, Hunter E, Dezfouli M, Salter M, Powel R, Ding A, Green J, Akoulitchev A, Amezquita R, Ching K, Pu J, Deng S, di Pietro A, Davis CB September 10, 2022 ESMO 2022 Urothelial Cancer

Genomic Biomarkers in Peripheral Blood (PB) From Patients (Pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

View Presentation
Poster
Aragon-Ching JB, Grivas P, Loriot Y, Bellmunt J, Wang J, Michelon E, di Pietro A, Powles T, Sridhar SS September 12, 2022 ESMO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From Patients With ≥12 Months of Treatment in JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Poster
Lapuente M, Milloy N, Berry M, Montgomery R, Bleasdale C, Kluth C, Kirker M, Kearney M, Costa N, Chang J September 12, 2022 ESMO 2022 Urothelial Cancer

Evaluating Real-World Caregiver Involvement From a Survey of Patients With Metastatic Urothelial Cancer (mUC) Receiving Systemic Anticancer Treatment in France, Germany, Italy, Spain, and the UK (Eu5)

View Presentation
Poster
Barthelemy P, Thibault C, Voog E, Eymard JC, Ravaud A, Flechon A, Abraham C, Hilgers W, Le Moulec S, Chasseray M, Pouessel D, Amela E, Lorgis V, Nicolas E, Kazan E, Denechere G, Solbes M-N, Lambert P, Loriot Y September 12, 2022 ESMO 2022 Urothelial Cancer

Preliminary Results From AVENANCE, an Ongoing, Noninterventional Real-World, Ambispective Study of Avelumab First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

View Presentation View Abstract Plain Language Summary
Oral Presentation
Eto M, Desai C, Park SH, Tsuchiya N, Su P-J, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Lee J-L December 2, 2022 ESMO Asia Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Longer-Term Follow-Up From the Asian Subgroup of the JAVELIN Bladder 100 Trial

View Presentation View Abstract Plain Language Summary
Poster
Milloy N, Berry M, Montgomery R, Kluth C, Bleasdale C, Kirker M, Kearney M, Mohamed W, Costa N, Chang J December 3, 2022 ESMO Asia Urothelial Cancer

First-Line (1L) Treatment Patterns and Criteria Used to Determine Platinum Eligibility (PE) in Platinum-Eligible and -Ineligible Patients With Metastatic Urothelial Cancer (mUC) in South Korea and Taiwan

View Presentation